CN103608029A - 包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物 - Google Patents

包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物 Download PDF

Info

Publication number
CN103608029A
CN103608029A CN201280031198.9A CN201280031198A CN103608029A CN 103608029 A CN103608029 A CN 103608029A CN 201280031198 A CN201280031198 A CN 201280031198A CN 103608029 A CN103608029 A CN 103608029A
Authority
CN
China
Prior art keywords
aflibercept
fluorouracil
irinotecan
crc
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280031198.9A
Other languages
English (en)
Chinese (zh)
Inventor
R.卡斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46001286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103608029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN103608029A publication Critical patent/CN103608029A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201280031198.9A 2011-04-26 2012-04-25 包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物 Pending CN103608029A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305490.2 2011-04-26
EP11305490 2011-04-26
EP11306154 2011-09-15
EP11306154.3 2011-09-15
PCT/EP2012/057542 WO2012146610A1 (en) 2011-04-26 2012-04-25 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)

Publications (1)

Publication Number Publication Date
CN103608029A true CN103608029A (zh) 2014-02-26

Family

ID=46001286

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280031198.9A Pending CN103608029A (zh) 2011-04-26 2012-04-25 包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物

Country Status (39)

Country Link
US (1) US11033606B2 (https=)
EP (2) EP3210617A1 (https=)
JP (1) JP6114257B2 (https=)
KR (2) KR20190088568A (https=)
CN (1) CN103608029A (https=)
AR (1) AR086051A1 (https=)
AU (1) AU2012247530B2 (https=)
BR (1) BR112013027356A2 (https=)
CA (1) CA2833592A1 (https=)
CL (1) CL2013003082A1 (https=)
CO (1) CO6811861A2 (https=)
CR (1) CR20130547A (https=)
CY (1) CY1120382T1 (https=)
DK (1) DK2701724T3 (https=)
DO (1) DOP2013000248A (https=)
EA (1) EA025182B1 (https=)
EC (1) ECSP13013044A (https=)
ES (1) ES2637074T3 (https=)
GT (1) GT201300260A (https=)
HR (1) HRP20171216T1 (https=)
HU (1) HUE034288T2 (https=)
IL (2) IL228947B (https=)
JO (1) JO3283B1 (https=)
LT (1) LT2701724T (https=)
MA (1) MA35130B1 (https=)
MX (1) MX341348B (https=)
NI (1) NI201300112A (https=)
PE (2) PE20171516A1 (https=)
PH (1) PH12013502195A1 (https=)
PL (1) PL2701724T3 (https=)
PT (1) PT2701724T (https=)
RS (1) RS56177B1 (https=)
SG (2) SG194613A1 (https=)
SI (1) SI2701724T1 (https=)
TW (1) TWI599369B (https=)
UA (1) UA114708C2 (https=)
UY (1) UY34036A (https=)
WO (1) WO2012146610A1 (https=)
ZA (1) ZA201308821B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853763A (zh) * 2012-08-02 2015-08-19 赛诺菲 包含阿柏西普或ziv-阿柏西普的制品
CN108137672A (zh) * 2015-10-15 2018-06-08 阿特根公司 用于生产具有igg fc结构域的融合蛋白的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
MX382673B (es) * 2014-09-16 2025-03-13 Regeneron Pharma Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR102652347B1 (ko) * 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
CA3101694A1 (en) * 2018-05-30 2019-12-05 David MACHOVER Methods and pharmaceutical compositions for treating cancer
WO2021050094A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101125141A (zh) * 2007-08-10 2008-02-20 河北医科大学 一种抗癌药物组合物及其在制备抗癌药物中的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790B2 (ja) 1977-11-18 1985-05-17 株式会社日立製作所 光硬化型接着性組成物とそれを用いて被着体を接着する方法
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
CA2158745C (en) 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19724793A1 (de) 1997-06-06 1998-12-10 Schering Ag D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
DE19938724A1 (de) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
AR028424A1 (es) 2000-05-10 2003-05-07 Bayer Corp Metodo para regular la angiogenesis utilizando proteina ryk
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040023864A1 (en) 2001-05-09 2004-02-05 Steve Roczniak Method of regulating angiogenesis using ryk protein
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
JP2005525367A (ja) 2002-03-01 2005-08-25 フアルマシア・イタリア・エツセ・ピー・アー 塩酸イリノテカンの結晶多形
JP2004006671A (ja) 2002-03-22 2004-01-08 Sanyo Electric Co Ltd 電荷結合素子およびその製造方法
WO2004087206A2 (en) 2003-03-28 2004-10-14 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US7300654B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection in high risk keratoplasty patients
CA2519835A1 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
WO2005017734A1 (ja) 2003-08-14 2005-02-24 Fujitsu Limited コンピュータ装置および集合サーバ装置
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
ATE423670T1 (de) 2003-11-06 2009-03-15 Nestle Waters Man & Technology Herstellungsverfahren von behältern aus polyesterharz
US7582726B2 (en) 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
MXPA06014689A (es) 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
JP5737826B2 (ja) 2005-03-11 2015-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆの阻害による貧血の処置
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2615636A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CA2680528A1 (en) 2007-03-23 2008-10-02 Precision Therapeutics, Inc. Methods for evaluating angiogenic potential in culture
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
CA2705792A1 (en) 2007-11-30 2009-06-11 Milan Radovich Vegf polymorphisms and anti-angiogenesis therapy
EP2143542A1 (fr) 2008-07-07 2010-01-13 Nestec S.A. Procédé et dispositif de conditionnement d'un liquide alimentaire
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US20100047314A1 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
DK2540843T3 (da) 2008-11-05 2014-09-01 Genentech Inc Genetiske polymorfismer ved aldersbetinget makulær degeneration
CA2754646A1 (en) 2009-03-31 2010-10-07 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
US20120100134A1 (en) 2009-04-24 2012-04-26 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome
PE20121189A1 (es) 2009-07-31 2012-09-06 Amcor Ltd Recipiente de llenado en caliente
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20130330341A1 (en) 2011-02-23 2013-12-12 Sanofi Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
JP6019790B2 (ja) 2012-06-19 2016-11-02 富士電機株式会社 接合方法及び接合部材
AU2013298521A1 (en) 2012-08-02 2015-02-26 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
EA035674B1 (ru) * 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
KR102652347B1 (ko) 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101125141A (zh) * 2007-08-10 2008-02-20 河北医科大学 一种抗癌药物组合物及其在制备抗癌药物中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.VERSLYPE等: "Validation of the selectd dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients(pts) with advanced solid tumors (STs): Preliminary results", 《JOURNAL OF CLINICAL ONCOLOGY》 *
HERBERT HURWITZ等: "Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
SANOFI-REGENERON: "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen", 《CLINICALTRIALS.GOV》 *
杨林等: "结直肠癌内科治疗进展", 《癌症进展杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853763A (zh) * 2012-08-02 2015-08-19 赛诺菲 包含阿柏西普或ziv-阿柏西普的制品
CN108137672A (zh) * 2015-10-15 2018-06-08 阿特根公司 用于生产具有igg fc结构域的融合蛋白的方法
CN108137672B (zh) * 2015-10-15 2022-09-06 阿特根公司 用于生产具有igg fc结构域的融合蛋白的方法
CN115247196A (zh) * 2015-10-15 2022-10-28 阿特根公司 用于生产具有igg fc结构域的融合蛋白的方法

Also Published As

Publication number Publication date
UA114708C2 (uk) 2017-07-25
BR112013027356A2 (pt) 2016-11-29
ECSP13013044A (es) 2014-01-31
DK2701724T3 (en) 2017-09-11
JP6114257B2 (ja) 2017-04-12
CL2013003082A1 (es) 2014-05-16
EP2701724A1 (en) 2014-03-05
EA025182B1 (ru) 2016-11-30
PH12013502195A1 (en) 2022-04-08
TW201247220A (en) 2012-12-01
TWI599369B (zh) 2017-09-21
IL228947B (en) 2018-01-31
US20140051642A1 (en) 2014-02-20
PT2701724T (pt) 2017-08-18
LT2701724T (lt) 2017-09-11
NI201300112A (es) 2014-02-28
CY1120382T1 (el) 2019-07-10
IL257179A (en) 2018-03-29
HRP20171216T1 (hr) 2017-10-20
JO3283B1 (ar) 2018-09-16
CR20130547A (es) 2014-02-18
EP3210617A1 (en) 2017-08-30
ES2637074T3 (es) 2017-10-10
MX2013012387A (es) 2014-12-05
ZA201308821B (en) 2015-01-28
GT201300260A (es) 2015-02-09
IL228947A0 (en) 2013-12-31
AU2012247530B2 (en) 2017-05-11
AR086051A1 (es) 2013-11-13
PL2701724T3 (pl) 2017-11-30
KR102002653B1 (ko) 2019-07-24
NZ617573A (en) 2015-11-27
CA2833592A1 (en) 2012-11-01
MX341348B (es) 2016-08-17
WO2012146610A1 (en) 2012-11-01
AU2012247530A1 (en) 2013-05-02
SI2701724T1 (sl) 2017-10-30
HUE034288T2 (en) 2018-02-28
KR20140036193A (ko) 2014-03-25
SG10201610829UA (en) 2017-02-27
RS56177B1 (sr) 2017-11-30
SG194613A1 (en) 2013-12-30
MA35130B1 (fr) 2014-05-02
PE20171516A1 (es) 2017-10-20
JP2014513089A (ja) 2014-05-29
EA201391577A1 (ru) 2014-03-31
CO6811861A2 (es) 2013-12-16
US11033606B2 (en) 2021-06-15
DOP2013000248A (es) 2014-02-28
KR20190088568A (ko) 2019-07-26
UY34036A (es) 2012-11-30
EP2701724B1 (en) 2017-05-24
PE20140616A1 (es) 2014-05-24

Similar Documents

Publication Publication Date Title
CN103608029A (zh) 包含阿柏西普、亚叶酸、5-氟尿嘧啶(5-fu)和伊立替康(folfiri)的组合物
Papadopoulos et al. A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors
US20180036395A1 (en) Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
Hu et al. Trop2-targeted therapy in breast cancer
JP2011511074A (ja) 結腸直腸癌を治療するためのピコプラチンおよびセツキシマブの使用
Pfeiffer et al. Current role of antibody therapy in patients with metastatic colorectal cancer
WO2014006113A1 (en) Method of treating cancer by effective amounts of aflibercept
Parrasia et al. Targeting pancreatic ductal adenocarcinoma (PDAC)
Rossi et al. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making
Wang et al. Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma
Turkington et al. A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma
OA16640A (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI).
HK1239531A1 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
Gunturu et al. Highlights on the first line treatment of metastatic pancreatic cancer
HK1189506A (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
HK1189506B (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
NZ617573B2 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
Comella et al. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience
MACNEIL et al. Vemurafenib and ipilimumab plus dacarbazine extend survival in metastatic melanoma
Edelman et al. Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161021

Address after: France

Applicant after: SANOFI SA

Address before: France

Applicant before: Sai Nuofei

RJ01 Rejection of invention patent application after publication

Application publication date: 20140226

RJ01 Rejection of invention patent application after publication